Peregrine Pharmaceuticals reported $149.96M in Cash and Equivalent for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agenus AGEN:US $ 247.71M 44.22M
Amgen AMGN:US $ 6528M 1461M
AstraZeneca AZN:LN 5762M 567M
Biocryst Pharmaceuticals BCRX:US $ 395.5M 108.88M
Bristol Myers Squibb BMY:US $ 12369M 1610M
Celldex Therapeutics CLDX:US $ 25.29M 13.85M
Chemocentryx CCXI:US $ 40.58M 9.4M
Eli Lilly And LLY:US $ 2459.2M 1359.3M
GlaxoSmithKline GSK:LN 10967M 6693M
Immunogen IMGN:US $ 437.66M 41.09M
Intrexon XON:US $ 40.32M 2.6M
Karyopharm Therapeutics KPTI:US $ 153.26M 37.2M
Mannkind MNKD:US $ 67.24M 56.94M
Merk MRK:US $ 8556M 460M
Minerva Neurosciences NERV:US $ 54.95M 5.81M
Newlink Genetics NLNK:US $ 86.76M 8.05M
Novartis NOVN:VX SF 13852M 1445M
Novavax NVAX:US $ 1570.95M 1209.13M
Peregrine Pharmaceuticals PPHM:US $ 149.96M 13.72M
Repligen RGEN:US $ 584.64M 19.17M
Xencor XNCR:US $ 78.27M 65.21M